Drugs / SHP640
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT02998541 | Mar 2017 → May 2019 | viral conjunctivitis | Shire | Terminated | No outcome recorded Stop: Business |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SHP640 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02998541 ↗ |
| Route | Other | “Participants will receive one drop of SHP640 (0.1 % dexamethasone and 0.6% PVP-I) ophthalmic suspension in each eye QID (with a minimum of 2 hours between doses) for 7 days.” NCT02998541 ↗ |